/
AGIO
$37.11-$0.93 (-2.44%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$2.3B
59M shares
52-week range
$22.24 – $46.00
63% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.41%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-19.31
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $94.4M | $117.9M | $0 | $0 | $14.2M | $26.8M | $36.5M | $54.0M |
| Cost of revenue | $1.4M | $1.3M | $18.8M | $18.8M | $1.7M | $9.5M | $4.2M | $11.5M |
| Gross profit | $93.0M | $116.6M | −$18.8M | −$18.8M | $12.5M | $17.3M | $32.3M | $42.5M |
| Gross margin | 98.5% | 98.9% | — | — | 88.0% | 64.6% | 88.6% | 78.7% |
| R&D | $341.3M | $410.9M | $211.0M | $257.0M | $279.9M | $288.9M | $301.3M | $334.4M |
| Operating income | −$362.5M | −$426.3M | −$335.9M | −$378.4M | −$389.0M | −$391.5M | −$425.7M | −$472.1M |
| EBITDA | −$338.9M | −$394.9M | −$310.5M | −$337.7M | −$223.2M | −$345.5M | $723.6M | −$408.6M |
| Net income | −$346.0M | −$411.5M | −$327.4M | $1.60B | −$231.8M | −$352.1M | $673.7M | −$412.8M |
| Net margin | -366.6% | -349.0% | — | — | -1627.8% | -1312.6% | 1845.9% | -764.0% |
| EPS (diluted) | -6.03 | -6.61 | -4.74 | -6.36 | -4.23 | -6.33 | 11.64 | -7.12 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $122M | $-6.23 | $-7.18–$-5.46 | 8 |
| 2027 | $257M | $-4.77 | $-5.74–$-3.61 | 8 |
| 2028 | $392M | $-3.45 | $-4.77–$-1.40 | 8 |
| 2029 | $531M | $-1.91 | $-2.61–$-1.14 | 6 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$4.00
Price
$37.11
Implied downside
-89%
Peer comparison
Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
www.agios.com- Employees
- 540
- IPO / List date
- Jul 24, 2013
- HQ
- CAMBRIDGE, MA
Held by traders on TradeandTell
No one on the platform currently holds AGIO.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in AGIO as of their last filing.
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded AGIO yet.
